The Largest Pharmaceutical Companies in Egypt 2026: Local and Global
Egypt's pharmaceutical market reached $8.5 billion in 2025 (up 37% from the previous year), moving Egypt up to 26th worldwide (from 30th in 2024), with a compound annual growth rate of about 15% — almost double the global average. Local factories now cover 91% of domestic consumption, but Egypt still imports more than 90% of the raw materials needed for manufacturing.
First: the largest Egyptian companies listed on the stock exchange
EIPICO (Egyptian International Pharmaceutical Industries Company)
The largest private drug manufacturer in Egypt, listed on the stock exchange (ticker PHAR), and on the Forbes Middle East list of the 50 largest Egyptian companies 2026 with a market value of $278 million.
- Ownership: the Arab Company for Drug Industries and Medical Appliances (ACDIMA) owns 51.3%
- 2025 revenue: EGP 9,441 million (+24%)
- 2025 net profit: EGP 1,441.7 million (+32%)
- Size: 3 factories, 51 production lines, more than 300 million units a year, 400+ products
- Exports: 60 countries, accounting for 22% of the company's total business
- 2026: a new joint venture, "Arab API", to manufacture pharmaceutical raw materials locally with a $165 million investment
GSK Egypt
The Egyptian branch of the global British company GSK, listed on the stock exchange (ticker BIOC).
- 2025 net sales: EGP 3.73 billion (from 2.99 billion in 2024)
- 2025 consolidated net profit: EGP 213.2 million (+22.56%)
Second: major private companies (unlisted or with limited disclosure)
EVA Pharma
A family company (led by Dr. Riad Armanious), one of the largest biotech pharmaceutical companies in Egypt and the region.
- Size: more than 5,000 employees, production capacity of about one million packs a day, 3 factories in Egypt plus a factory in Saudi Arabia and branches in Hungary and Germany
- 2024: it began manufacturing long-acting insulin (glargine) locally in partnership with the US company Eli Lilly — an important achievement for the Egyptian pharmaceutical industry in advanced therapies
Pharco Pharmaceuticals
A private Egyptian company (chairwoman: Sherine Helmy), one of the few companies that has announced clear sales figures.
- 2025 sales: about EGP 15 billion, with a target of EGP 18 billion for 2026
- Targeted market share: about 9% locally
- Gulf expansion: a new factory west of Madinah in Saudi Arabia with an investment of about $150 million, expected to start production in early 2028; Saudi Arabia accounts for about 50% of the company's export revenue
- 2026: a new eye-drop production line with an investment of EGP 500 million (capacity of 20 million packs a year)
Amoun Pharma — an important ownership note
One of the largest generic drug companies in Egypt, but not entirely Egyptian-owned: in 2021 the Canadian company Bausch Health sold it to Abu Dhabi's sovereign fund ADQ for $740 million (about 99%). The company exports to about 25-29 countries and has about 2,500 employees and 26 production lines.
CID (Sedico)
One of the companies linked to the ACDIMA group (the same group that owns part of EIPICO, though the link needs further confirmation). In 2025-2026 it opened a new factory for cancer drugs at a cost of EGP 1 billion, with expected sales of EGP 1.4 billion within 3 years, and drugs priced 30-60% lower than imports.
Other prominent companies
- Minapharm — one of the oldest private pharmaceutical companies in Egypt (late 1950s), a biotech pioneer that launched the first Egyptian pegylated interferon in 2005 and helped significantly lower the cost of hepatitis C treatment.
- Marcyrl Pharmaceutical Industries — founded in 1998, it received investment from the DPI and Amethis funds in 2023, specializing in antibiotics and hormone therapy.
- Sanofi Egypt — the branch of the global French company, operating in Egypt since 1961, with more than 1,100 employees; more than 77% of its available products are manufactured locally.
Exports: a target of $3 billion by 2030
Egyptian pharmaceutical exports reached about $1.3 billion by the end of 2025, and the Egyptian Drug Authority aims to reach $3 billion by 2030 (of which $1.34 billion for African markets). Pharmaceuticals have become Egypt's second-largest industrial export category.
Frequently Asked Questions
Which is the largest pharmaceutical company in Egypt? EIPICO is the largest as a listed private Egyptian company with fully documented financials, but a precise comparison of the "largest" is difficult because other companies such as EVA Pharma and Amoun are very large but don't publish consolidated annual revenue with full transparency.
Are all pharmaceutical companies in Egypt Egyptian-owned? No — Amoun is owned by Abu Dhabi's sovereign fund, GSK and Sanofi are branches of global companies, while EIPICO, Pharco, and EVA Pharma are Egyptian in origin and ownership.
Sources: official company reports (Investing.com, Arab Finance for EIPICO), Zawya for the 2025 Egyptian pharmaceutical market size report, Middle East Observer for manufacturing and export data, Daily News Egypt and EnterpriseAM for coverage of Pharco and CID, Forbes Middle East for the 2026 list of Egyptian companies. Last updated: August 2026.